Biomimetic scaffolds imitate native tissue and can take a multidimensional form. They are
biocompatible and can influence cellular metabolism, making them attractive bioengineering …

Adoptive cell therapies engineered to express chimeric antigen receptors (CARs) or
transgenic T cell receptors (TCRs) to recognize and eliminate cancer cells have emerged as …

Acute myeloid leukemia (AML) poses a singular challenge for chimeric antigen receptor
(CAR) therapy owing to its phenotypic heterogeneity and similarity to normal hematopoietic …

Haematopoietic stem cell (HSC) transplantation (HSCT) is the only curative treatment for a
broad range of haematological malignancies, but the standard of care relies on untargeted …

Acute myeloid leukemia (AML) is a malignant cancer characterized by abnormal
differentiation of hematopoietic stem and progenitor cells (HSPCs). While chimeric antigen …

Engineering immune cells to treat hematological malignancies has been a major focus of
research since the first resounding successes of CAR-T-cell therapies in B-ALL. Several …

Engineering T cell specificity and function at multiple loci can generate more effective
cellular therapies, but current manufacturing methods produce heterogenous mixtures of …

T-cell redirecting therapies (TCRTs), such as CAR-or TCR T-cells and T-cell engagers, have
emerged as a highly effective treatment modality, particularly in the B-and plasma cell …

Clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing
has begun to transform the treatment landscape of genetic diseases. The history of the …

We developed an in vivo hematopoietic stem cell (HSC) gene therapy approach that does
not require cell transplantation. To achieve therapeutically relevant numbers of corrected …